Manica Balasegaram
@Manica_amr
Followers
1K
Following
1K
Media
109
Statuses
987
Executive Director of @gardp_amr and doctor dedicated to clinical and public health practice in infectious diseases, health policy & access to medicines.
Geneva, Switzerland
Joined April 2019
We need a new approach to antibiotics. My latest piece on how more than 50 million deaths could be prevented by increasing access to antibiotics, published in @wef
https://t.co/g2ICbzBa4B
weforum.org
As the majority of people worldwide lack access to effective antibiotics, the most difficult-to-treat infections are now outpacing antibiotic development.
0
7
15
We’re thrilled to welcome Dr. José Gomes Temporão to GARDP’s Board! As our first Board member from #LATAC, he brings invaluable expertise to the fight against #AMR. 📢 Learn more: https://t.co/lxiCXy8QI9
0
4
13
Infections are the 2nd leading cause of deaths for cancer patients. Without new #antibiotics, survival rates could start to decline On this #WorldCancerDay, let’s commit to fighting #cancer & #AMR. Because survival should mean a second chance at life - not another battle for it
0
6
10
How more than 50 million deaths could be prevented by increasing access to antibiotics 💊 Read @Manica_amr piece in @wef 👇 https://t.co/HjZertwREy
weforum.org
As the majority of people worldwide lack access to effective antibiotics, the most difficult-to-treat infections are now outpacing antibiotic development.
0
3
5
📢 #WorldNTDDay is this Thursday 30 January! This is a chance to raise awareness for the 1 billion+ people affected by neglected tropical diseases! How you can help: 1️⃣ Download our messaging materials: https://t.co/OYz7bZeQNg 2️⃣ Share them on your channels this week. #BeatNTDs
0
21
27
As 2024 comes to a close, I’m proud of what we’ve achieved together. None of this would have been possible without the dedication, expertise, and passion of our team. Together, we’ll keep pushing forward to deliver life-saving treatments to those who need them most.
2024 was a pivotal year in the fight against #AMR💫 🔬 Zoliflodacin Phase 3 results 👶 Launch of NeoSep1 trial 🤝Cefiderocol tech transfer 🌍 New partnerships in India, Latin America & Korea 💡 EUR 60M in pledges More in "2024: A Year in Review" 👇 https://t.co/RD8WZ0neq1
0
0
6
Policy and regulatory interventions to address antibiotic shortages in low and middle-income countries https://t.co/5k6o0ylagN
0
1
2
Very honored to accept this award as a recognition of the work of GARDP and its key partners, especially our partnership with Innoviva Speciality Therapuetics, Inc. for the development of zoliflodacin.
Yesterday our Executive Director @Manica_amr was in #NYC for the #Fierce50 awards gala. ✨ The #Fierce50 is a groundbreaking project that highlights the people & companies driving meaningful change in #healthcare, pharma and #biotech. Manica accepted the award for the
0
0
4
Fascinating article that deserves a more in-depth unpacking. It’s also relevant considering the evolved challenges in the antibiotic space today. https://t.co/DAHNDydiaw
journals.plos.org
Debates over the scope, terms, and governance of technology transfer–the sharing of essential technical information, know-how, and materials needed to manufacture a health product–are prominent and...
0
2
5
Yesterday our Executive Director @Manica_amr was in #NYC for the #Fierce50 awards gala. ✨ The #Fierce50 is a groundbreaking project that highlights the people & companies driving meaningful change in #healthcare, pharma and #biotech. Manica accepted the award for the
0
2
6
India could be at the forefront of the solution. With its scientific expertise, clinical resources and pharmaceutical sector, India has everything it needs to not only to tackle the AMR crisis within its borders but also to lead the way. https://t.co/02vm3crYVm
thehindu.com
India has everything it needs to not only reverse the AMR crisis within its own borders but also to lead the way in the global response
1
3
6
Excellent article on India’s locally developed new drugs and the game-changing solution they offer to preserve last-resort treatments. We need more innovation and to learn from past mistakes. https://t.co/A3GgThvdyT
bbc.com
A number of promising new drugs from India show potential to fight antibiotic-resistant bacteria.
1
7
24
We're looking forward to the #Fierce50 ceremony! GARDP's Executive Director, @Manica_amr, has been lauded as a 2024 #Fierce50 honoree! 🎉 This recognition highlights his work in driving progress in the fight against #AMR.
0
2
6
Conflicts often create conditions that are perfect for emergence and spread of drug resistance, a phenomenon first documented as early as the 1940s. https://t.co/AYOp6ZDQLE
nytimes.com
Researchers are trying to understand why resistant pathogens are so prevalent in the war-torn nations of the Middle East.
0
0
1
Thanks @VikasReports for this great discussion about India's potential influence in tackling AMR.
Explore India’s potential influence in tackling #AMR in this episode of #ETMorningBriefPodcast by @EconomicTimes, with @Manica_amr 🎙️Tune in now https://t.co/uQN3VAqyMO
@VikasReports
0
2
3
It’s antibiotic awareness week! #AntimicrobialResistance (AR) kills an estimated 1 million people every year & is one of the greatest health threats we face today. To learn more about how to prevent AR, including through responsible antibiotic use, visit https://t.co/eIVzO8mvWd
16
8
18
Hear from Takuko Sawada, Director and Vice Chairperson of the Board, Shionogi & Co., Ltd. and Manica Balasegaram, Executive Director of @gardp_amr, about how we are working together to increase access to antibiotics, as part of addressing #AMR. #WAAW
https://t.co/B24VI4gWLL
0
3
9
The Superbug Fight Needs a Better Business Model https://t.co/ERIRHtKdg7
globalhealthnow.org
The current pipeline for new antibiotics is “on the verge of collapse” within the next four to eight years—and a key reason is that antibiotic makers can’t stay in business.
0
0
3
Public-health driven R&D and access is what we need, not just for antibiotics but for all conditions that affect children. We are happy to be part of the GAP-f network to ensure that children, particularly in low- and middle-income countries, have equitable access to medicines.
Advancing #paediatric formulations is crucial to ensure equitable, evidence-based care for #children with serious bacterial infections. The report on #WHO's technical consultation which aims to facilitate regulatory pathways to accelerate access to effective treatments is
0
0
0
The Race Against Antimicrobial Resistance in Neonates: Insights on Data, Infection Prevention, and Stewardship Date: Tuesday, November 19, 2024 Africa Times: 11:30 p.m. GMT | 12:30 p.m. WAT | 1:30 p.m. CAT | 2:30 p.m. EAT Register: https://t.co/jjtvm7bjlq...
0
2
2
Great discussions today with Ambassador @MayaTissafi on AMR in India and around the world. With allies like Switzerland, GARDP is strengthening its efforts to tackle this pressing global health challenge.
0
0
7